Expanding Treatment Possibilities with GentiBio’s Autologous & Allogenic Therapeutic Development
4:00 pm - Wednesday 25th March 2026
• Exploring early clinical insights and data from GNTI-122 combatting T1D
• Uncovering GentiBio’s shielding technology to refine allogenic therapies
• Translating allogenic technology into Treg products
